74 related articles for article (PubMed ID: 15333686)
1. A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer.
Sheen WC; Chen JS; Wang HM; Yang TS; Liaw CC; Lin YC
Jpn J Clin Oncol; 2004 Jun; 34(6):337-41. PubMed ID: 15333686
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
[TBL] [Abstract][Full Text] [Related]
3. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
[TBL] [Abstract][Full Text] [Related]
4. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
Eklund J; Kozloff M; Vlamakis J; Starr A; Mariott M; Gallot L; Jovanovic B; Schilder L; Robin E; Pins M; Bergan RC
Cancer; 2006 Jun; 106(11):2459-65. PubMed ID: 16615097
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice.
Dowling AJ; Czaykowski PM; Krahn MD; Moore MJ; Tannock IF
J Urol; 2000 May; 163(5):1481-5. PubMed ID: 10751862
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
Chan JS; Beer TM; Quinn DI; Pinski JK; Garzotto M; Sokoloff M; Dehaze DR; Ryan CW
BJU Int; 2008 Dec; 102(11):1601-6. PubMed ID: 18782306
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.
Daliani DD; Assikis V; Tu SM; Papandreou CN; Pagliaro LC; Holtkamp T; Wang X; Thall PF; Logothetis CJ
Cancer; 2003 Feb; 97(3):561-7. PubMed ID: 12548597
[TBL] [Abstract][Full Text] [Related]
11. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
Samelis GF; Kalofonos H; Adamou A; Kosmides P; Skarlos D; Aravantinos G; Kiamouris C; Adimchi O; Fountzilas G; Dimopoulos AM
Urology; 2005 Aug; 66(2):382-5. PubMed ID: 16098366
[TBL] [Abstract][Full Text] [Related]
12. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.
Raghavan D; Brandes LJ; Klapp K; Snyder T; Styles E; Tsao-Wei D; Lieskovsky G; Quinn DI; Ramsey EW
J Urol; 2005 Nov; 174(5):1808-13; discussion 1813. PubMed ID: 16217292
[TBL] [Abstract][Full Text] [Related]
14. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
Chi KN; Gleave ME; Klasa R; Murray N; Bryce C; Lopes de Menezes DE; D'Aloisio S; Tolcher AW
Clin Cancer Res; 2001 Dec; 7(12):3920-7. PubMed ID: 11751483
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
Hellerstedt B; Pienta KJ; Redman BG; Esper P; Dunn R; Fardig J; Olson K; Smith DC
Cancer; 2003 Oct; 98(8):1603-10. PubMed ID: 14534875
[TBL] [Abstract][Full Text] [Related]
16. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
[TBL] [Abstract][Full Text] [Related]
17. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.
Ansari MS; Gupta NP
Urol Oncol; 2004; 22(5):415-20. PubMed ID: 15464923
[TBL] [Abstract][Full Text] [Related]
18. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
Vaughn DJ; Brown AW; Harker WG; Huh S; Miller L; Rinaldi D; Kabbinavar F
Cancer; 2004 Feb; 100(4):746-50. PubMed ID: 14770430
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.
Huan SD; Natale RB; Stewart DJ; Sartiano GP; Stella PJ; Roberts JD; Symes AL; Finizio M
Clin Cancer Res; 2000 Apr; 6(4):1333-6. PubMed ID: 10778959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
